Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies
Year: 2020
Type: conference-abstract
Source: Cancer Research
Authors: Antonio Jimeno, Shilpa Gupta, Ryan Sullivan, Khanh T. Do, Wallace L. Akerley, Ding Wang, Deanna Teoh, Kurt Schalper, Sima J. Zacharek, Jing Sun, Andressa S. Laino, Joshua Frederick, Honghong Zhou, William Randolph, Stephanie Pascarella, Lisa Johansen, Pamela S. Cohen, ROBERT S. MEEHAN, Todd M. Bauer
Institutions: University of Colorado Cancer Center, Cleveland Clinic, Massachusetts General Hospital, Dana-Farber Cancer Institute, University of Utah, Huntsman Cancer Institute, Henry Ford Hospital, University of Minnesota, University of Minnesota Medical Center, Yale University, Sarah Cannon, Tennessee Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3083291045